Developing a new vaccine platform to combat COVID-19 and future coronaviruses
Official title: Self-Assembling Spike-EBR Nanoparticles as a Vaccine Platform Technology Against SARS-CoV-2 and Future Pandemic Coronaviruses
Funded at J. David Gladstone Institutes · NIH-11123595 · Data updated 2026-11-12
This study is working on a new type of vaccine that uses tiny particles to help your body fight off COVID-19 and other coronaviruses better and for longer, so you might need fewer shots and get stronger protection against different virus strains.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | June 22, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $472,500 |
| NIH project number | 7DP5OD033362-03 |
| Project ID | NIH-11123595 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are at risk of COVID-19 infection or those who may benefit from enhanced vaccination strategies.
✕Less likely to help
Patients who are already fully vaccinated and have no risk factors for severe COVID-19 may not receive direct benefits from this research.
What this research studies
This research focuses on creating a novel vaccine technology using self-assembling nanoparticles to enhance the immune response against SARS-CoV-2 and other coronaviruses. By improving upon existing mRNA vaccine strategies, the project aims to develop vaccines that can provide stronger and longer-lasting protection with fewer doses. The approach involves designing vaccines that target conserved regions of the virus, which could help in generating a broader immune response against various strains. Patients may benefit from a more effective and accessible vaccine solution that can be rapidly deployed during pandemics.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide stronger immunity against COVID-19 and other coronaviruses.
How similar studies have gone: Other research has shown promising results with nanoparticle-based vaccine technologies, indicating potential for success in this novel approach.
Where this research is happening
-
J. David Gladstone Institutes
San Francisco, United States Active
Researchers
- Principal investigator: Hoffmann, Magnus Adrian Gero — J. David Gladstone Institutes
- Study coordinator: Hoffmann, Magnus Adrian Gero
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.